The goal of this clinical trial is to learn if a gel containing Piroxicam plus Counterirritant (warming/cooling ingredients) is as effective and safe as two other common anti-inflammatory gels for treating acute muscle, bone, and joint pain in adults aged 18-60. The main questions it aims to answer are: Does the Piroxicam plus Counterirritant gel provide a similar level of pain relief as the standard Piroxicam-only gel and the Diclofenac gel? Is the Piroxicam plus Counterirritant gel as safe to use as the other two gels? Researchers will compare three groups of participants, each using one of the gels (Piroxicam plus Counterirritant, Piroxicam-only, or Diclofenac) to see if the combination gel works equally well. Participants will: * Be randomly assigned to use one of the three gels for approximately 6 days. * Visit the clinic three times (at the start, midpoint, and end) for pain assessments, physical exams (checking movement and muscle strength), and physiotherapy sessions. * Apply their assigned gel at home three times daily (morning, afternoon, evening) and record their gel use and pain levels in a provided diary. * Receive a rescue medication (paracetamol) to use only if their pain becomes unbearable and record when they take it.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The primary end-point is the difference of musculoskeletal pain reduction > 3 scores , of the response to treatment that can be seen through Brief Pain Inventory (BPI) scores.
Timeframe: From enrollment to the end of treatment at 4 months